US2018148449A1PendingUtilityA1

Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof

Assignee: PURDUE PHARMA LPPriority: Jul 21, 2008Filed: Jan 23, 2018Published: May 31, 2018
Est. expiryJul 21, 2028(~2 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 9/12A61P 35/00A61P 29/00A61P 25/22A61P 25/04A61P 25/30A61P 25/24A61P 3/04A61P 3/00A61P 25/08A61P 25/00A61P 25/28A61P 25/16A61P 1/10A61P 1/12A61P 13/02A61P 13/00A61P 11/04A61P 11/14C07D 451/14C07D 471/08C07D 403/04A61K 31/498
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled) 
     
     
         47 . A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of a compound of Formula (I′): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable derivative thereof, wherein:
 each R 2  is independently selected from -halo; 
 a is 0, 1 or 2; 
 b is 0 or 1; 
 each R 5  is independently —H, —OH, —(C 1 -C 3 )alkyl, —C(halo) 3 , or -halo; 
 R 1  is —(C 9 -C 14 )cycloalkyl or —(C 9 -C 14 )bicycloalkyl, each of which is substituted with 1, 2 or 3 independently selected R 3  groups; 
 each R 3  is independently —(C 1 -C 4 )alkyl, —(C 2 -C 6 )alkenyl, —(C 2 -C 6 )alkynyl, or —(C 3 -C 6 )cycloalkyl. 
 
     
     
         48 - 53 . (canceled) 
     
     
         54 . The method of  claim 47 , wherein each R 5  is independently —H, —(C 1 -C 3 )alkyl, —C(halo) 3 , or -halo. 
     
     
         55 . The method of  claim 47 , wherein each R 5  is independently —H, —CH 3 , —CF 3 , or —F. 
     
     
         56 . The method of  claim 47 , wherein a is 0 or 1. 
     
     
         57 . The method of  claim 47 , wherein the compound is a compound of formula (II): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable derivative thereof. 
     
     
         58 . The method of  claim 57 , wherein the 3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid portion of the compound is in the endo-conformation with respect to the bridge of the bridged piperidine. 
     
     
         59 . The method of  claim 47 , wherein R 1  is —(C 9 -C 12 )cycloalkyl or —(C 9 -C 12 )bicycloalkyl. 
     
     
         60 . The method of  claim 47 , wherein R 1  is -indanyl, -1,2,3,4-tetrahydronaphthalenyl, -5,6,7,8-tetrahydronaphthalenyl, -perhydronaphthalenyl, bicyclo[3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[3.3.2]decyl, bicyclo[4.2.2]decyl, bicyclo[4.3.1]decyl, bicyclo[3.3.3]undecyl, bicyclo[4.3.2]undecyl, or bicyclo[4.3.3]dodecyl. 
     
     
         61 . The method of  claim 47 , wherein R 1  is bicyclo[3.3.1]nonyl. 
     
     
         62 . The method of  claim 61 , wherein R 1  is 2-bicyclo[3.3.1]nonyl or 3-bicyclo[3.3.1]nonyl. 
     
     
         63 . The method of  claim 47 , wherein R 1  is in the endo-conformation with respect to the bridge of the bridged piperidine of the compound. 
     
     
         64 . The method of  claim 47 , wherein b is 1. 
     
     
         65 . The method of  claim 47 , wherein R 1  is 
       
         
           
           
               
               
           
         
       
     
     
         66 . The method of  claim 47 , wherein said pain is said pain is acute pain or chronic pain. 
     
     
         67 . The method of  claim 47 , wherein said pain is inflammatory pain, neuropathic pain, or a combination thereof. 
     
     
         68 . The method of  claim 47 , wherein said compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable derivatives thereof. 
     
     
         69 . A method of treating pain in an animal, comprising administering to an animal identified in need thereof an effective amount of a compound of 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable derivative thereof. 
     
     
         70 . The method of  claim 69 , wherein said pain is acute pain or chronic pain.

Join the waitlist — get patent alerts

Track US2018148449A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.